Related Experiment Videos
Use of ceftazidime for malignant external otitis
1Department of Otolaryngology-Head and Neck Surgery, New York Eye and Ear Infirmary, New York Medical College, NY 10003.
The Annals of Otology, Rhinology, and Laryngology
|September 1, 1989
Summary
Ceftazidime effectively treats malignant external otitis, offering better outcomes and fewer side effects than older antibiotic combinations. This study reviews eight patient cases, highlighting improved cure rates and simpler administration for this serious Pseudomonas infection.
Area of Science:
- Infectious Diseases
- Otolaryngology
- Pharmacology
Background:
- Malignant external otitis (MEO) is a severe Pseudomonas aeruginosa infection.
- Previous treatments involved aminoglycosides and semisynthetic penicillins.
- Limited treatment options and significant toxicity were associated with prior therapies.
Observation:
- Ceftazidime, a third-generation cephalosporin, was administered to eight MEO patients.
- The antibiotic demonstrated high activity against Pseudomonas species.
- Ceftazidime achieved penetration into the cerebrospinal fluid (CSF).
Findings:
- Ceftazidime treatment resulted in improved cure rates compared to previous regimens.
- The drug exhibited lower toxicity profiles.
- Simplified administration schedules were noted with ceftazidime therapy.
Implications:
- Ceftazidime represents a more advantageous therapeutic option for MEO.
- This cephalosporin offers a potentially safer and more effective treatment strategy.
- Further investigation into ceftazidime for MEO is warranted based on these positive outcomes.